Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors

by Shah, Manisha H., Lorigan, Paul, O’Brien, Mary E. R., Fossella, Frank V., Moore, Kathleen N., Bhatia, Shailender, Kirby, Maurice, Woll, Penella J.
Published 2016

Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and...

by Cohen, Ezra EW, Moore, Kathleen N, Slomovitz, Brian M, Chung, Christine H, Anderson, Matthew L, Morris, Shannon R, Mauro, David, Burtness, Barbara
Published 2015

Phase 1, Open-Label, Dose Escalation, Safety, and Pharmacokinetics Study of ME-344 as a Single Agent in Patients With Refractory Solid Tumors

by Bendell, Johanna C, Patel, Manish R, Infante, Jeffrey R, Kurkjian, Carla D, Jones, Suzanne F, Pant, Shubham, Burris, Howard A, Moreno, Ofir, Esquibel, Vanessa, Levin, Wendy, Moore, Kathleen N
Published 2015